RALGPS2 and urinary bladder carcinoma: In this study, RalGPS2 emerges as a potential common pharmacological target for the development of TNTs-interfering drugs that can reduce tumor progression, at least in bladder cancer, by blocking supportive intercellular mechanisms within the tumor microenvironment.